Invesco Mutual FundEquity Schemes - Mid Cap Fund13.8 years
The scheme seeks to generate capital appreciation by investing predominantly in Midcap companies
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Three-year return is above the category median.
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Prefer peers if · Prefer HSBC Midcap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.76% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -34.1%. Ask whether you can hold through a similar fall.
Vs category
Watch
52% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Aditya Khemani · 3.0 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 49.1% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 34%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
20 Feb 2020 – 6 Nov 2020
Trough 23 Mar 2020 · recovered in 228 days
-34.1%
7 Jan 2013 – 9 Dec 2013
Trough 28 Aug 2013 · recovered in 103 days
-21.9%
16 Dec 2024 – 6 Jun 2025
Trough 28 Feb 2025 · recovered in 98 days
-20.1%
17 Jan 2022 – 1 Dec 2022
Trough 20 Jun 2022 · recovered in 164 days
-20.1%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
100
Vs category
49
Consistency
49
Risk-adjusted
69
Drawdown
15
Mean
56
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
No status reasons yet. History is still thin.
Supporting reads
30 Sept 2026 · 44 holdings · top 10 are 49.1%.
Prestige Estates Projects Ltd
Real Estate
7.3%
Max Healthcare Institute Ltd
Healthcare
7.2%
Meesho Ltd.
Consumer Discretionary
5.4%
The Federal Bank Ltd
Financial
5.4%
Manipal Health Enterprises Ltd
Healthcare
4.4%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
27 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
26 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
23 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
22 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
10 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
8 Sept 2026
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
HSBC Mutual Fund
Caveat: Higher volatility · Higher TER
WhiteOak Capital Mutual Fund
Caveat: Higher TER · Lower trailing returns
Kotak Mahindra Mutual Fund
Caveat: Deeper drawdown · Lower trailing returns
Helios Mutual Fund
Caveat: Higher volatility · Higher TER · Lower trailing returns
JM Financial Mutual Fund
Caveat: Higher volatility · Higher TER · Lower trailing returns
Invesco Mutual FundEquity Schemes - Mid Cap Fund13.8 years
The scheme seeks to generate capital appreciation by investing predominantly in Midcap companies
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Three-year return is above the category median.
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Prefer peers if · Prefer HSBC Midcap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.76% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -34.1%. Ask whether you can hold through a similar fall.
Vs category
Watch
52% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Aditya Khemani · 3.0 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 49.1% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 34%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
29 Oct 2026 · -0.1% over 1Y
224.92
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
29 Oct 2026
-8.8%
20 Feb 2020 – 6 Nov 2020
Trough 23 Mar 2020 · recovered in 228 days
-34.1%
7 Jan 2013 – 9 Dec 2013
Trough 28 Aug 2013 · recovered in 103 days
-21.9%
16 Dec 2024 – 6 Jun 2025
Trough 28 Feb 2025 · recovered in 98 days
-20.1%
17 Jan 2022 – 1 Dec 2022
Trough 20 Jun 2022 · recovered in 164 days
-20.1%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
100
Vs category
49
Consistency
49
Risk-adjusted
69
Drawdown
15
Mean
56
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
No status reasons yet. History is still thin.
Supporting reads
30 Sept 2026 · 44 holdings · top 10 are 49.1%.
Prestige Estates Projects Ltd
Real Estate
7.3%
Max Healthcare Institute Ltd
Healthcare
7.2%
Meesho Ltd.
Consumer Discretionary
5.4%
The Federal Bank Ltd
Financial
5.4%
Manipal Health Enterprises Ltd
Healthcare
4.4%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
27 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
26 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
23 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
22 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
10 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
8 Sept 2026